BioXcel Therapeutics, Inc.

The BioFuture conference in New York featured panels that got into the nitty-gritty of drug development – from using artificial intelligence to improve the efficiency of drug development, to finding i

BioAge Labs, Inc. switched the development focus for its lead drug candidate, the small molecule apelin receptor (APJ) agonist azelaprag, from age-related muscle loss to prevention of muscle loss in

Otsuka Pharmaceutical Co. Ltd. has now decided to fully terminate the development of its neuropsychiatric compound AVP-786 following a Phase III failure reported earlier this year. The decision is in

Otsuka Holdings Co., Ltd. currently has the only therapy on the market for agitation associated with dementia due to Alzheimer’s disease, but its attempt to advance another therapy as a back-up has f